We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

MedImaging

Download Mobile App
Recent News Radiography MRI Ultrasound Nuclear Medicine General/Advanced Imaging Imaging IT Industry News

Pacemakers Receive CE Mark with Options for MRI

By MedImaging International staff writers
Posted on 10 Nov 2014
Print article
A range of pacemakers have received CE marking approval, and they are the first to enable patients to undergo full-body magnetic resonance imaging (MRI) scans in both 1.5 Tesla and 3.0 Tesla systems.

When implanted with the Ingevity leads, Accolade pacemakers enable patients to receive full-body MRI scans. Moreover, Boston Scientific’s (Marlborough, MA, USA) ImageReady technology offers the most flexible MRI options, allowing higher energy scan sequences, and featuring a programmable MRI timer designed to improve patient workflow.

The first Accolade device implant was performed by a group coordinated by Prof. Francesco Romeo, director of the cardiology department of Fondazione Policlinico Tor Vergata (Rome, Italy), and president-elect of Italian Society of Cardiology (SIC). “Thanks to the Accolade pacemaker family, I can offer my patients the best pacing therapies while giving them unparalleled access to imaging,” said Prof. Romeo. “Additionally, the full suite of diagnostics and the excellent longevity of the device mean that I should be able to utilize the device for my patients undergoing MRI scans in the future—many years from now.”

In addition to the CE marking approval and introduction of the Accolade pacemaker family, Boston Scientific received CE Marking approval for the Visionist and Valitude cardiac resynchronization therapy pacemakers (CRT-Ps) with quadripolar pacing technology. When combined with the Acuity X4 pacing leads, these systems offer many options to reach and pace the target location in the left ventricle, potentially improving the patient response to CRT therapy. Dr. Stuart Harris, clinical director of the Essex Cardiothoracic Center (Basildon, UK), performed the first implant of the Visionist X4 system.

“We have prioritized investments and now have the first and only subcutaneous ICD, the smallest ICD [cardioverter defibrillator], and the longest-lasting pacemaker, ICD and CRT devices in the world,” said Joe Fitzgerald, executive vice president and president, rhythm management. “Now, with the Accolade pacemaker family, we also offer the most flexible MRI-conditional pacemaker system, along with advanced diagnostics that assist physicians in detecting atrial arrhythmias. We believe that the provision of automatic daily monitoring and advanced diagnostics to our pacemaker devices will help physicians identify atrial fibrillation sooner, enabling them to initiate patient anti-coagulation therapy to reduce the risk of stroke.”

Boston Scientific is also actively pursuing MRI compatibility for their line of existing ICDs, cardiac resynchronization therapy defibrillators (CRT-Ds), including the Autogen, Dynagen, Inogen, and Origen CRT-Ds, and lead technologies such as the Ingevity, Reliance, and Acuity leads.

The Accolade, Visionist, Valitude, Autogen, Origen, Ingevity, and Acuity X4 devices are not yet available for sale in the United States.

Related Links:

Boston Scientific


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Brachytherapy Planning System
Oncentra Brachy
New
Ultrasound System
P20 Elite
PACS Workstation
CHILI Web Viewer

Print article

Channels

Ultrasound

view channel
Image: CAM figures of testing images (Photo courtesy of SPJ; DOI:10.34133/research.0319)

Diagnostic System Automatically Analyzes TTE Images to Identify Congenital Heart Disease

Congenital heart disease (CHD) is one of the most prevalent congenital anomalies worldwide, presenting substantial health and financial challenges for affected patients. Early detection and treatment of... Read more

Nuclear Medicine

view channel
Image: Whole-body maximum-intensity projections over time after [68Ga]Ga-DPI-4452 administration (Photo courtesy of SNMMI)

New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients

Clear cell renal cell cancer (ccRCC) represents 70-80% of renal cell carcinoma cases. While localized disease can be effectively treated with surgery and ablative therapies, one-third of patients either... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more